Reuters logo
BRIEF-Intarcia Therapeutics says FDA has issued a CRL for ITCA 650
September 27, 2017 / 9:45 PM / 2 months ago

BRIEF-Intarcia Therapeutics says FDA has issued a CRL for ITCA 650

Sept 27 (Reuters) - Intarcia Therapeutics Inc

* Intarcia Therapeutics says U.S. FDA has issued a Complete Response Letter (CRL) for ITCA 650 (exenatide implant) for treatment of type 2 diabetes​

* ‍intarcia - does not anticipate need to conduct new pivotal trials or any long lead-time CMC activities in order to satisfy requirements of U.S. FDA​ Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below